DSG Consumer Partners.
India's original consumer-only VC: 93+ first cheques since 2013, Sula from inception to listing, OYO's most profitable early cheque (up to ~180x on the first $125K), L'Oréal as a strategic LP, and a deliberately contrarian 2026 thesis: the 'anti-AI premium'.
GW GP Score
Deepak Shahdadpuri has run one thesis for two decades: Indian consumption formalises, brands compound, get in first (52 of 93+ positions were first institutional cheques). The receipts run from Sula (2004 entry, listed 2022, board seat 2024) to OYO ($125K at $1.5M valuation, fully exited by 2018 at up to ~180x on the first cheque) to Veeba, Epigamia and Mosaic Wellness. Fund IV ($114M, 72% existing-LP re-up, L'Oréal strategic) stays deliberately small. The 2026 letter is pure contrarian positioning: capital efficiency as true north, an 'anti-AI premium' on real-world experiences, quick-commerce as default distribution.
Conditional hold: enough signal to track closely, not enough to underwrite without the next proof point.
Portfolio quality depends on a narrow theme; the right comp is concentration risk, not headline unicorn count.
No named analyst override yet; current view is generated from the scored dossier and should be refreshed when the next primary source lands.
Fund V: no raise announced; timing tells us about consumer-LP appetite.
DSGCP-entity Sula shareholding post-IPO: never separately disclosed.
Structurally short the AI rotation: same exposure as Fireside with even less tech adjacency.
Computed from current dossier sources; analyst override pending.
The consumer-specialist original: disciplined, re-upped, contrarian by conviction. Stable, with the anti-AI stance as a deliberate bet the platform's other 33 firms are taking the other side of.
Sula listed, Mosaic ~$400M, Farmley L Catterton-validated, Veeba/Epigamia compounding
18 exits incl. the OYO legend, but thin since 2024
Deep consumer moat, deliberately anti-cycle
72% re-up + L'Oréal; unhurried Fund V
Two decades, one thesis, no churn
Portfolio quality 25% · Exit realisation 30% · Sector positioning 15% · Capital velocity 15% · Franchise stability 15%: see the full GP Score methodology · compare this firm →
Current evidence supports the score, but not enough to move it without a fresh exit, fund close or team signal.
Mosaic Wellness liquidity clears with credible OFS/block-sale evidence.
Separate broad PE-VC softness from venture AI strength before changing sector-positioning scores.
Fund V: no raise announced; timing tells us about consumer-LP appetite.
DSGCP is the cohort's cleanest uncorrelated allocation: consumer-only, small-fund, 72% re-up. Pair it against your AI exposure: one of the two theses is mispriced, and DSG's 'anti-AI premium' letter tells you exactly which side it took.
Structurally short the AI rotation: same exposure as Fireside with even less tech adjacency.
Fund V: no raise announced; timing tells us about consumer-LP appetite.
Coverage initiated: inaugural GW GP Score.
Catalyst exposure · latest source pressure
Recent public evidence mapped to this GP. Read this before reading the position table: it is where the score can move next.
Keep the file warm; current events cut both ways or are not yet material enough to move score.
Attribution0 positive catalyst(s), 1 pressure catalyst(s); top driver: India PE-VC value down 5% YoY in H1 CY2026.
The broad private-capital backdrop is selective rather than euphoric; fundraising and mark support now need firm-specific proof.
Score pressureRaises the bar for weak-DPI managers and stale flagship vehicles; rewards funds with fresh closes or visible exits.
Separate broad PE-VC softness from venture AI strength before changing sector-positioning scores.
The funds
$300M+ across 2 tracked vehicles.
| Vehicle | Vintage | Size | Stage | Note |
|---|---|---|---|---|
| DSGCP IV | 2023Trough window | $114M | Seed + early-growth sleeve | $80M core + $34M growth; 72% re-up; L'Oréal BOLD strategic LP |
| DSGCP I-III + BOII | 2013-19Foundation era | $12.5M / $50M / $65M / $35M | Seed consumer | Sula/Veeba/Epigamia/OYO vintages |
Fund analytics · LP underwriting screen
Computed from the public dossier: vehicle cadence, realised exits, mark drift, concentration and franchise stability. All computed signals are GW estimates.
Vehicle cadence is neither freshly restocked nor visibly stale.
Next liquidityMosaic Wellness
1 visible exit events since Jul 2024.
Vehicle cadence is neither freshly restocked nor visibly stale.
6 up / 1 flat / 0 down tracked signals.
No senior departure flagged in key people.
6 up / 1 flat / 0 down
1 events since Jul 2024
Largest tracked active exposure
Higher spread = less balanced franchise
Best entry conditions of the cycle
Pre-unicorn pricing; discovery-cost entries
~$400M mark (Think Investments, Apr 2025)
At least one cited source is dated 2026.
1 visible events tracked.
9 representative positions tracked.
No departure signal structured.
Fund-level DPI/TVPI is usually not public; proxy remains estimated.
Peer median 2 · -1
Peer median 2 · -1
Peer median 74 · -6
Peer median 62 · +25
Peer median 0 · +0
Diligence agenda · how this view can change
The live research question, the proof required, and the source standard. This prevents a GP score from becoming a stale label.
Exit data, Team data, Performance proxy evidence remains low-confidence despite a scored dossier.
Current · At least one cited source is dated 2026.
Upgrade the weak fields with dated facts before the next score action: Exit data, Team data, Performance proxy.
Prioritise filings and firm disclosures; mark estimates as GW E until then.
DSGCP-entity Sula shareholding post-IPO: never separately disclosed.
Mosaic Wellness: next public-market or secondary print
Evidence quality · source file health
How hard the public record is beneath this view: source mix, freshness, low-confidence fields and the next source action.
Low-confidence fields: Exit data, Team data, Performance proxy.
5 total sources · 40% primary
At least one cited source is dated 2026.
DS Musings #181: 2026 outlook (firm, Dec 2025)
Upgrade Exit data evidence before changing the score.
Source tiering follows Gravitywell policy: primary = filing/regulator/company disclosure, secondary = reputable media or research, E = Gravitywell estimate. Evidence score is a GW control metric, not an external rating.
The position book
93-107 positions since 2013, 52 as first institutional cheque. 9 tracked below.
| Company | Sector | Entered | Entry stage | Status | 12-mo signal | Latest read |
|---|---|---|---|---|---|---|
| Sula Vineyards | Consumer & Commerce | 2004 | First institutional (pre-DSGCP) | Public | → | Listed Dec 2022; founder rejoined board 2024; DSGCP-entity sales undisclosed |
| Veeba | Consumer & Commerce | 2014 | First institutional | Private | ▲ | Condiments; serves Burger King, Domino's |
| Epigamia | Consumer & Commerce | 2014 | Seed | Private | ▲ | Turned profitable; rebuffed sale talk; co-founder's death (Dec 2024) navigated |
| Mosaic Wellness | Healthcare | 2020 | Early | Soonicorn | ▲ | ~$400M mark (Think Investments, Apr 2025) |
| 82°E | Consumer & Commerce | 2022 | Early | Private | · | Deepika Padukone prestige skincare |
| Farmley | Consumer & Commerce | 2022 | Series A | Private | ▲ | $42M L Catterton Series C (May 2025): markup |
| Go Zero | Consumer & Commerce | 2023 | Seed | Private | ▲ | Zero-sugar ice cream |
| WanderOn | Consumer & Commerce | 2026 | Series A co-led (₹54 Cr) | Private | · | Experiential travel: the anti-AI-premium thesis in action |
| Pickup Coffee | Consumer & Commerce | 2023 | Early | Private | ▲ | Philippines: the SEA sleeve |
Representative tracked positions reconstructed from public disclosures: not the full book. 12-mo signal is a GW estimate of mark direction from round/exit prints (E). Ownership stakes are not shown: not reliably public.
Sector exposure · where the book leans
Share of the tracked active book by normalized sector (GW estimate): read against our sector dossiers for crowding.
New cheques · 2025-26
Fourteen cheques in 2025 with the 2026 letter as the map: IRL experiences over screens ('anti-AI premium'), clinical efficacy over clean-label marketing, quick-commerce-native distribution, vertical integration. Nobody else in the cohort is underwriting AGAINST the AI premium: that's the point.
With CAAF
Beverages
Realisation · are LPs getting paid?
The realisation legend is historical (OYO 2018, Sula's listing); the 2024-26 window has been quiet: one SEA acquisition, no India realisations, and the firm's own Sula post-IPO sales are undisclosed. Consumer compounding is patient by design; Fund V's raise will test how patient LPs remain.
SEA restaurant-booking platform acquired by Grab: terms undisclosed.
Fund IV: the strongest public LP-satisfaction proxy available
Full 2018 exit; range depends on cheque counted (E)
No rush ~3 years post-Fund IV: consistent with small-fund creed
Chope only; Sula sales undisclosed
No DPI public; the 72% re-up and L'Oréal's strategic entry are the professional-grade signals. GW read: the discipline is real (fund sizes barely grew in a decade) and the thesis is genuinely uncorrelated with the cohort, which is either diversification or obsolescence, and 2026-27 consumer listings will say which. E.
What they're doing
Consumer-only, first-cheque-first: 52 of 93+ positions were the company's first institutional money.
Small funds forever: $114M Fund IV a decade in: returns over AUM.
The 2026 contrarian stack: anti-AI premium (IRL experiences), clinical efficacy, quick-commerce distribution, vertical integration.
India + SEA barbell (Singapore base; Philippines/Vietnam sleeve).
What can break
Structurally short the AI rotation: same exposure as Fireside with even less tech adjacency.
Realisation drought: brand equity ages if the 18-exit record stays pre-2024.
Founder-brand concentration: Shahdadpuri IS the firm after two decades.
Fund V: no raise announced; timing tells us about consumer-LP appetite.
DSGCP-entity Sula shareholding post-IPO: never separately disclosed.
Mosaic Wellness path (IPO chatter at ~$400M mark).
Point-in-time discipline: these are the open items we could not verify at the current vintage. They get resolved: confirmed, corrected or dropped, at the next monthly refresh, never silently.
The takes · one screen, three readers
DSGCP is the cohort's cleanest uncorrelated allocation: consumer-only, small-fund, 72% re-up. Pair it against your AI exposure: one of the two theses is mispriced, and DSG's 'anti-AI premium' letter tells you exactly which side it took.
Shahdadpuri sees Indian consumer founders a round before everyone (52 first cheques). Fireside competes with him for the same founders; everyone else should just read his Musings letters as sector research.
The DSG book is the longitudinal dataset on Indian brand formalisation: Sula to Go Zero is twenty years of the same thesis. WanderOn is the tell: experiential consumption as the next margin pool.
Sourcing. Every figure is sourced and dated. We tier provenance: Primary (official, regulatory, exchange or company filings), Secondary (tier-1 industry research and reputable media), and GW estimate (our own reconstruction or opinion, labelled, never presented as external fact). We prefer primary where it exists, reconcile divergent prints to cited ranges, and hold every number point-in-time: dated, and never silently restated; revisions publish as dated changes.
Fact vs opinion. Facts vs opinion: market sizes, official prints, prices, named deals and agency ratings are sourced facts (Primary/Secondary). Scores, grades, purity weights, scenario paths and indicative sparkline points are Gravitywell's analytical opinion (GW estimate): labelled, not presented as external data.
GW GP Scores are research opinions, not investment advice, not a solicitation, and not an assessment under any SEBI regulation. Dossiers are compiled from public sources believed reliable; firms named did not participate and figures marked E are Gravitywell estimates. Point-in-time: dated to the vintage shown and never silently restated.